FDA signs off on Merck’s cholesterol-lowering pill — the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes elevated levels of LDL.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- MRKMerck & Company Named
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
2 reports over 6h 27m-
New York Post Business You're reading this FDA signs off on Merck's cholesterol-lowering pill - the first oral treatment of its kind Neutral 0
